Viz.ai has announced its support for the MINUTE trial, which is a prospective, multicentre, randomised study evaluating whether the Scuba technique—an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracranial haemorrhage (ICH)—is a promising alternative to standard medical management in potentially improving patients’ functional outcomes.
The MINUTE trial is being led by a distinguished group of investigators from leading US academic medical centres, including J Mocco (Weill Cornell Medicine, New York, USA), Sharon Yeatts (Medical University of South Carolina, Charleston, USA), Magdy Selim (Beth Israel Deaconess Medical Center, Boston, USA), Joseph Broderick (University of Cincinnati, Cincinnati, USA) and Pooja Khatri (Yale School of Medicine, New Haven, USA).
“Ultra-early intervention represents an important potential avenue to improve ICH care,” said Mocco, who reports an equity interest in Viz.ai. “Technologies that help teams rapidly identify patients and coordinate care across disciplines are critical to facilitate the time-sensitive treatment windows this study is designed to evaluate.”
MINUTE aims to initiate both randomisation and surgical intervention within 120 minutes of key clinical timepoints, reflecting the urgent nature of ICH care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to support rapid identification, triage and care coordination for potentially eligible patients across participating centres.
According to Viz.ai, the company’s Viz Neuro Suite combines artificial intelligence (AI)-powered imaging analysis with real-time communication tools designed to accelerate care coordination across clinical teams. Additionally, Viz ICH enables early detection of suspected ICH on non-contrast computed tomography (CT) imaging, while Viz ICH Plus provides automated hyperdensity volume quantification on every scan.
The platform also uses Viz Assist to deliver an AI-driven chart summarisation, surfacing relevant clinical history, medications and prior notes to help clinicians rapidly contextualise patient data and coordinate across neurosurgery, neurology, and emergency medicine teams. Viz.ai notes in a press release that, for a trial where every minute is clinically meaningful, this combination of imaging AI and generative summarisation can help participating sites work toward the ultra-early intervention window outlined in the MINUTE protocol.
“ICH remains one of the most time-sensitive and devastating neurological emergencies, with outcomes heavily dependent on how quickly the right care team is mobilised,” commented Tim Showalter, chief medical officer of Viz.ai. “We are proud to support the MINUTE trial with our Viz Neuro Suite platform, helping investigators and clinical teams move faster and more decisively in identifying patients who may benefit from ultra-early surgical intervention.”
